Gritstone bio announced that a paper detailing the development of its “off-the-shelf” neoantigen platform, SLATE, recently published in Nature Medicine. The paper, “A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results,” describes a novel immunodominance hierarchy of tumor neoantigens that Gritstone discovered in Phase 1 translational studies and leveraged to develop SLATE-KRAS. “The publication of these findings in Nature Medicine highlights the promise of our ‘off-the-shelf’ or shared neoantigen approach in solid tumors, one of the many elements embedded within our mission to develop the world’s most potent vaccines,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio. “Our team’s innovative work to develop, optimize and validate SLATE positions Gritstone with two promising platforms to execute against our neoantigen-directed approach to oncology. It also enabled the pioneering collaboration that we are currently advancing with Dr. Rosenberg of the NCI, a luminary in the field. SLATE is ready for ‘plug and play’ application across a spectrum of solid tumors and could serve as a great complementary platform to GRANITE, our personalized vaccine program. We continue to have great conviction that both approaches could unlock new levels of immune responses for patients with solid tumors.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRTS:
- Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
- Gritstone presents improvements to EDGE Platform at AACR 2024
- Biotech Alert: Searches spiking for these stocks today
- Gritstone $32.5M Spot Secondary priced at $1.50
- Gritstone price target raised to $5 from $4 at JMP Securities